(Q42292098)

English

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer

scientific article published on 8 March 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

object named as

Jacek Jassem

1 reference

Europe PubMed Central

20 October 2017

PMC publication ID

7

object named as

Fadi Braiteh

1 reference

Europe PubMed Central

20 October 2017

PMC publication ID

Herbert Hurwitz

20

object named as

Herbert Hurwitz

1 reference

Europe PubMed Central

20 October 2017

PMC publication ID

5

object named as

Ira Gore

1 reference

Europe PubMed Central

20 October 2017

PMC publication ID

author name string

Rocío García-Carbonero

1

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Eric van Cutsem

2

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Fernando Rivera

3

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Niall Tebbutt

6

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Guillem Argiles

8

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Zev A Wainberg

9

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Roel Funke

10

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Maria Anderson

11

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Bruce McCall

12

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Mark Stroh

13

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Eric Wakshull

14

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Priti Hegde

15

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Weilan Ye

16

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Daniel Chen

17

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Ilsung Chang

18

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Ina Rhee

19

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

publication date

8 March 2017

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

22

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

4

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

375-e30

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

Cellular abnormalities of blood vessels as targets in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

VE-statin, an endothelial repressor of smooth muscle cell migration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

26 October 2017

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

17 August 2018

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

17 August 2018

Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

17 August 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5388369

1 December 2018

Identifiers

10.1634/THEONCOLOGIST.2016-0133

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42292098&oldid=2119130862"